推荐产品
等级
pharmaceutical primary standard
API类
abiraterone
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
C[C@]12C(C[C@@H](OC(C)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CC=CN=C5
InChI
1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
InChI key
UVIQSJCZCSLXRZ-UBUQANBQSA-N
基因信息
human ... CYP17A1(1586)
正在寻找类似产品? 访问 产品对比指南
一般描述
Abiraterone acetate is a pro-drug of abiraterone and a potent inhibitor of the enzyme CYP17, required for androgen biosynthesis in the adrenal glands, testes and prostate tissue.
应用
Abiraterone acetate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Abiraterone Acetate Tablets
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
危险分类
Aquatic Chronic 1 - Repr. 1B - STOT RE 2
靶器官
Endocrine system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
Danila.CD, et al.
Journal of Clinical Oncology, 28(9), 1496- 1501 (2010)
Ryan.JC, et al.
Journal of Clinical Oncology, 28(9), 1481-1488 (2010)
Abiraterone Acetate Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 26-26 (2022)
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response
Ryan.JC, et al.
Clinical Cancer Research, 14(7), 4854-4861 (2011)
Abiraterone Acetate
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 25-25 (2020)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门